Gossamer Bio (GOSS) Reiterated at Overweight by Cantor Fitzgerald: Phase 3 Readout in Feb

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Gossamer Bio Inc. (NASDAQ: GOSS).

The analyst commented, "The phase 3 PROSERA study (seralutinib in PAH) is expected to readout in mid to late February. There's a lot of enthusiasm coming from Gossamer into their data, and we think they have a real drug on their hands. The Week 24 6MWD will be the most important data point (stat sig is a must), but having data from 120+ patients out to Week 48 will go a long way in assessing seralutinib's effect over time. Plus, the imaging data that'll get presented in 2Q26 could make a big splash."

For an analyst ratings summary and ratings history on Gossamer Bio Inc. click here. For more ratings news on Gossamer Bio Inc. click here.

Shares of Gossamer Bio Inc. closed at $2.74 yesterday.

You May Also Be Interested In

• Freedom Broker Double Downgrades Mosaic (MOS) to Sell
• Brinker Int'l (EAT) PT Raised to $285 at UBS Following 'Impressive' Q4 Outperformance
• MongoDB (MDB) PT Raised at RBC Capital; 'Shares represent an attractive buying opportunity'